Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Bradley Corr

Concepts (221)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
23
2026
205
6.970
Why?
Ovarian Neoplasms
14
2025
604
2.990
Why?
Neoplasm Recurrence, Local
10
2025
1160
2.290
Why?
beta Catenin
5
2025
250
2.040
Why?
Antineoplastic Combined Chemotherapy Protocols
14
2025
1998
1.810
Why?
Carcinoma, Endometrioid
3
2022
49
1.730
Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2025
139
1.630
Why?
Antibodies, Monoclonal, Humanized
8
2026
992
1.410
Why?
Phenylurea Compounds
4
2025
122
1.290
Why?
Quinolines
4
2025
191
1.240
Why?
Wnt Signaling Pathway
3
2025
211
0.910
Why?
Phthalazines
1
2025
64
0.870
Why?
Lymph Nodes
2
2018
511
0.830
Why?
Uterine Cervical Neoplasms
6
2024
269
0.790
Why?
Piperazines
1
2025
368
0.760
Why?
Indoles
1
2025
511
0.670
Why?
Wnt Proteins
1
2021
131
0.630
Why?
Aged, 80 and over
23
2025
8391
0.620
Why?
Mutation
6
2025
4093
0.590
Why?
Tumor Suppressor Protein p53
5
2025
530
0.580
Why?
Camptothecin
3
2025
139
0.580
Why?
Immunoconjugates
3
2025
138
0.570
Why?
Female
50
2026
79499
0.520
Why?
Drug Resistance, Neoplasm
7
2025
893
0.500
Why?
Adenocarcinoma, Mucinous
1
2018
76
0.500
Why?
Practice Patterns, Physicians'
2
2025
1408
0.480
Why?
Antineoplastic Agents
5
2025
2219
0.480
Why?
Middle Aged
34
2026
36619
0.470
Why?
Gynecologic Surgical Procedures
2
2020
68
0.470
Why?
Keratin-5
1
2015
43
0.450
Why?
Neoplasms, Glandular and Epithelial
1
2015
52
0.440
Why?
Aged
29
2026
26432
0.440
Why?
Venous Thromboembolism
2
2020
332
0.440
Why?
Cisplatin
2
2023
347
0.430
Why?
Hysterectomy
4
2019
139
0.420
Why?
Humans
54
2026
146342
0.390
Why?
Bile Ducts, Intrahepatic
1
2013
62
0.390
Why?
Neoplasm Grading
4
2025
313
0.370
Why?
Microsatellite Instability
2
2025
57
0.360
Why?
Cholangiocarcinoma
1
2013
110
0.360
Why?
Biomarkers, Tumor
6
2025
1339
0.360
Why?
Adult
28
2026
41087
0.350
Why?
Bile Duct Neoplasms
1
2013
132
0.350
Why?
Cell Line, Tumor
5
2025
3545
0.340
Why?
Genital Neoplasms, Female
3
2024
100
0.340
Why?
Lymph Node Excision
3
2018
174
0.330
Why?
Cerebral Palsy
2
2025
149
0.330
Why?
Molecular Targeted Therapy
2
2025
447
0.310
Why?
Gene Expression Regulation, Neoplastic
3
2025
1432
0.280
Why?
Maytansine
2
2025
18
0.270
Why?
Pyrimidinones
2
2025
124
0.250
Why?
Immunotherapy
3
2025
671
0.250
Why?
Bevacizumab
3
2025
169
0.250
Why?
MutL Protein Homolog 1
1
2026
11
0.240
Why?
Immunohistochemistry
2
2023
1712
0.230
Why?
Sensorimotor Cortex
1
2025
8
0.230
Why?
Homologous Recombination
1
2025
38
0.230
Why?
Maintenance Chemotherapy
1
2025
41
0.220
Why?
Cell Survival
2
2021
1105
0.220
Why?
CTLA-4 Antigen
1
2025
105
0.220
Why?
DNA Mismatch Repair
4
2026
54
0.220
Why?
Drug Synergism
1
2025
354
0.210
Why?
Folate Receptor 1
1
2024
17
0.210
Why?
Xenograft Model Antitumor Assays
2
2025
930
0.210
Why?
Uterine Neoplasms
1
2025
98
0.200
Why?
Cystadenocarcinoma, Serous
1
2025
90
0.200
Why?
Tryptophan Oxygenase
1
2024
33
0.200
Why?
Pyrazoles
3
2025
517
0.190
Why?
DNA Polymerase II
2
2023
35
0.190
Why?
Poly-ADP-Ribose Binding Proteins
2
2023
35
0.190
Why?
Exercise Therapy
2
2025
488
0.190
Why?
Gait
1
2025
322
0.180
Why?
Tertiary Care Centers
1
2023
196
0.180
Why?
Fallopian Tube Neoplasms
1
2022
20
0.180
Why?
Neoplasms
3
2022
2954
0.170
Why?
Thrombocytopenia
1
2023
206
0.170
Why?
Radiosurgery
1
2025
398
0.170
Why?
Heterocyclic Compounds, 3-Ring
1
2021
44
0.170
Why?
DNA Methylation
1
2026
725
0.160
Why?
Indazoles
1
2021
86
0.160
Why?
Disease Progression
3
2025
2867
0.160
Why?
Precision Medicine
1
2025
462
0.160
Why?
Retrospective Studies
7
2025
17438
0.160
Why?
Clinical Trials, Phase I as Topic
1
2020
49
0.160
Why?
Benzoxazoles
1
2020
20
0.160
Why?
Double-Blind Method
1
2025
2070
0.160
Why?
High-Throughput Nucleotide Sequencing
1
2023
539
0.150
Why?
Cohort Studies
5
2026
6077
0.150
Why?
Neoplasm Staging
3
2019
1488
0.150
Why?
Imidazoles
1
2021
245
0.150
Why?
Azepines
1
2020
104
0.150
Why?
Enoxaparin
1
2020
68
0.150
Why?
Disease Susceptibility
1
2021
339
0.150
Why?
Mindfulness
1
2021
134
0.150
Why?
Machine Learning
1
2025
594
0.140
Why?
Survival Analysis
3
2020
1378
0.140
Why?
Margins of Excision
1
2019
55
0.140
Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
111
0.140
Why?
Pyridones
1
2020
210
0.140
Why?
Frozen Sections
1
2018
23
0.130
Why?
Recurrence
1
2021
1133
0.130
Why?
PTEN Phosphohydrolase
1
2019
166
0.130
Why?
Oncologists
1
2018
47
0.130
Why?
Protein Kinase Inhibitors
2
2023
983
0.130
Why?
Cross-Sectional Studies
3
2018
5899
0.130
Why?
Postural Balance
1
2020
249
0.130
Why?
Colorectal Neoplasms
1
2025
874
0.120
Why?
Preoperative Care
2
2017
396
0.120
Why?
Disease Management
1
2021
651
0.120
Why?
Pyridines
1
2021
610
0.120
Why?
Pyrimidines
1
2020
532
0.120
Why?
Minority Groups
1
2018
286
0.120
Why?
Amyotrophic Lateral Sclerosis
3
2003
98
0.120
Why?
Gynecology
1
2018
185
0.120
Why?
Tissue Array Analysis
1
2015
49
0.110
Why?
Perioperative Period
1
2015
69
0.110
Why?
Neoplasm Invasiveness
1
2017
504
0.110
Why?
Radiography, Thoracic
1
2016
174
0.110
Why?
Anticoagulants
1
2020
746
0.110
Why?
Laparotomy
1
2015
111
0.100
Why?
Heparin
1
2015
247
0.100
Why?
Surgeons
1
2018
351
0.100
Why?
Disease Models, Animal
1
2024
4580
0.100
Why?
Platinum
2
2025
48
0.100
Why?
Quality of Health Care
1
2018
702
0.100
Why?
Magnetoencephalography
2
2025
161
0.090
Why?
Treatment Outcome
3
2020
11821
0.090
Why?
Receptors, Estrogen
1
2015
406
0.090
Why?
Membrane Proteins
1
2019
1130
0.090
Why?
Paclitaxel
2
2025
260
0.090
Why?
Combined Modality Therapy
2
2013
1271
0.090
Why?
Ovary
1
2013
236
0.090
Why?
Robotic Surgical Procedures
1
2015
210
0.090
Why?
Case-Control Studies
1
2019
3647
0.080
Why?
Prognosis
5
2023
4351
0.080
Why?
Maximum Tolerated Dose
2
2022
217
0.080
Why?
Breast Neoplasms
1
2024
2418
0.080
Why?
Young Adult
6
2025
14330
0.080
Why?
Chemoradiotherapy
2
2025
238
0.080
Why?
Mice
2
2025
18297
0.080
Why?
Postoperative Complications
2
2020
3034
0.080
Why?
Prospective Studies
4
2023
8123
0.080
Why?
Tumor Microenvironment
2
2024
747
0.070
Why?
Cell Proliferation
1
2015
2502
0.070
Why?
Animals
3
2025
38107
0.070
Why?
Adolescent
6
2025
22557
0.060
Why?
Apoptosis
1
2015
2439
0.060
Why?
Germ-Line Mutation
1
2026
180
0.060
Why?
Genomic Instability
1
2025
64
0.050
Why?
Retreatment
1
2025
79
0.050
Why?
Neoplastic Syndromes, Hereditary
1
2025
47
0.050
Why?
GPI-Linked Proteins
1
2025
81
0.050
Why?
Carboplatin
1
2025
168
0.050
Why?
Carbonyl Reductase (NADPH)
1
2024
5
0.050
Why?
Wnt4 Protein
1
2024
19
0.050
Why?
Programmed Cell Death 1 Receptor
1
2025
268
0.050
Why?
Cell Adhesion Molecules
1
2024
180
0.050
Why?
Kynurenine
1
2024
114
0.050
Why?
Disease-Free Survival
1
2025
778
0.050
Why?
Mesylates
1
2022
7
0.050
Why?
Antigens, Neoplasm
1
2024
271
0.050
Why?
Topoisomerase I Inhibitors
1
2022
20
0.050
Why?
Tryptophan
1
2024
184
0.050
Why?
AMP-Activated Protein Kinases
1
2024
193
0.050
Why?
Lung Neoplasms
1
2016
2675
0.050
Why?
Registries
3
2018
2400
0.040
Why?
Ligands
1
2024
678
0.040
Why?
Somatosensory Cortex
1
2022
42
0.040
Why?
B7-H1 Antigen
1
2024
245
0.040
Why?
Promoter Regions, Genetic
1
2026
1242
0.040
Why?
Antibodies, Bispecific
1
2022
70
0.040
Why?
Ambulatory Care Facilities
1
2003
269
0.040
Why?
Quality of Life
2
2025
3200
0.040
Why?
Enzyme Inhibitors
1
2024
823
0.040
Why?
Decision Trees
1
2000
76
0.040
Why?
Aurora Kinase A
1
2020
57
0.040
Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.040
Why?
Interleukin-6
1
2024
784
0.040
Why?
Vascular Endothelial Growth Factor A
1
2022
545
0.040
Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
141
0.040
Why?
Physical Examination
1
2020
237
0.040
Why?
Randomized Controlled Trials as Topic
1
2025
1763
0.030
Why?
Adenine
1
2020
339
0.030
Why?
Neoplasm Metastasis
1
2020
693
0.030
Why?
Patient Care Team
1
2003
701
0.030
Why?
Ireland
3
2003
33
0.030
Why?
Program Evaluation
1
2021
952
0.030
Why?
Walking
1
2022
546
0.030
Why?
Physical Therapy Modalities
1
2020
341
0.030
Why?
Regression Analysis
1
2019
999
0.030
Why?
Macrophages
1
2024
1532
0.030
Why?
Brain Neoplasms
1
2025
1325
0.030
Why?
RNA
1
2022
926
0.030
Why?
Neoadjuvant Therapy
1
2018
475
0.030
Why?
Ileus
1
2015
14
0.030
Why?
Salpingectomy
1
2015
15
0.030
Why?
Urinary Retention
1
2015
23
0.030
Why?
Ovariectomy
1
2015
164
0.030
Why?
Blood Loss, Surgical
1
2015
117
0.030
Why?
Survival Rate
1
2019
2092
0.020
Why?
Pelvis
1
2015
129
0.020
Why?
Logistic Models
1
2018
2126
0.020
Why?
Pandemics
1
2021
1707
0.020
Why?
Caregivers
1
2021
1080
0.020
Why?
Patient Readmission
1
2018
778
0.020
Why?
Follow-Up Studies
2
2018
5439
0.020
Why?
Referral and Consultation
1
2018
881
0.020
Why?
United States
2
2019
16136
0.020
Why?
Signal Transduction
1
2024
5246
0.020
Why?
Male
5
2025
73396
0.020
Why?
Length of Stay
1
2015
1358
0.020
Why?
Immunotherapy, Adoptive
1
2012
356
0.020
Why?
Patient Discharge
1
2015
997
0.020
Why?
Diagnosis, Differential
2
2003
1503
0.020
Why?
Age Factors
1
2015
3347
0.020
Why?
Antibodies, Monoclonal
1
2012
1512
0.010
Why?
Interprofessional Relations
1
2003
275
0.010
Why?
Child
1
2020
22693
0.010
Why?
Central Nervous System Diseases
1
2000
73
0.010
Why?
Age of Onset
1
2000
558
0.010
Why?
Palliative Care
1
2003
1032
0.010
Why?
Corr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)